Výsledky vyhledávání - "Robert Asbury"

Weekly paclitaxel in advanced non[ndash ]small cell lung cancer

Autor: Jonathan Rubins, Alex Y. Chang, Lai Fong Hui, Laszlo Boros, Robert Asbury

Publikováno v: Seminars in Oncology. 28:10-13

Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is one of the most commonly used agents in treating patients with locally advanced and metastatic non-small cell lung cancer (NSCLC). It is usually given once every 3 weeks. We have eval

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c54ff2fc1ebfb011f4ce322a2a192bd9
https://doi.org/10.1053/sonc.2001.27607

Zobrazit plný text záznamu

Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists

Autor: Gary R. Morrow, Robert Asbury, Sharon Hammon, Patricia Dobkin, Libby Caruso, Kishan Pandya, Susan Rosenthal

Publikováno v: Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 11(4)

Adequate control of side effects during medical treatment of cancer increases patient compliance and quality of life. Antiemetic drugs are not an effective treatment for the one in three cancer patients on chemotherapy who experience anticipatory nau

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aab3f9b4f3aff841569b9dca1af7696
https://pubmed.ncbi.nlm.nih.gov/1396493

Zobrazit plný text záznamu

P3-132: A Phase II trial of docetaxel, oxaliplatin and bevacizumab as first–line therapy of unresectable, locally advanced or recurrent and/or metastatic (Stage IIIB/IV) non–small cell lung cancer (NSCLC)– initial safety analysis

Autor: Robert Asbury, Luis E. Raez, Timothy Webb, Nicholas Sarlis, Edgardo S. Santos, William Babcock, M. Karr, Rogelio Brito, Khaled A. Tolba

Publikováno v: Journal of Thoracic Oncology. 2:S735

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c0d1f4e596bdd10329929a41973d87e
https://doi.org/10.1097/01.jto.0000284107.34082.1b

Zobrazit plný text záznamu

Mitoxantrone (NSC-3O1739) in patients with advanced ovarian carcinoma

Autor: Brian N. Bundy, Hyman B. Muss, Robert Asbury, Clarence E. Ehrlich, James Graham

Publikováno v: American Journal of Clinical Oncology. 7:737-740

Twenty-six evaluable patients with advanced epithelial ovarian cancer were treated with mitoxantrone at a dosage of 12 mg/m2 every three weeks. One patient had a partial response; four, stable disease; the remainder progressed. Mitoxantrone used in t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5cabf72ef25af76b596451a14b01eca6
https://doi.org/10.1097/00000421-198412000-00026

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání